SAR-442501 is under clinical development by Sanofi and currently in Phase I for Achondroplasia. According to GlobalData, Phase I drugs for Achondroplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SAR-442501 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-442501 is under development for the treatment of achondroplasia and osteochondrodysplasia. It is an antibody acts by targeting Fgfr3. It is administered through subcutaneous route.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of SAR-442501’s drug-specific PTSR and LoA scores, buy the report here.